Zentalis Pharmaceuticals Inc’s filing revealed that its Director Skvarka Jan acquired Company’s shares for reported $0.1 million on Jan 31 ’25. In the deal valued at $1.72 per share,60,000 shares were bought. As a result of this transaction, Skvarka Jan now holds 149,551 shares worth roughly $0.24 million.
Then, Walker Luke Nathaniel bought 14,200 shares, generating $24,966 in total proceeds. Upon buying the shares at $1.76, the Director now owns 86,681 shares.
Before that, EASTLAND JULIA MARIE bought 28,500 shares. Zentalis Pharmaceuticals Inc shares valued at $49,345 were divested by the CEO & President at a price of $1.73 per share. As a result of the transaction, EASTLAND JULIA MARIE now holds 28,500 shares, worth roughly $46455.0.
Wedbush upgraded its Zentalis Pharmaceuticals Inc [ZNTL] rating to a Neutral from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including UBS’s analysts, who decreased its forecast for the stock in mid June from “a Buy” to “a Neutral”. Wells Fargo also remained covering ZNTL and has decreased its forecast on June 18, 2024 with a “an Equal weight” recommendation from previously “an Overweight” rating. Wedbush revised its rating on June 18, 2024. It rated ZNTL as “an Underperform” which previously was an “a Neutral”.
Price Performance Review of ZNTL
On Tuesday, Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] saw its stock fall -2.98% to $1.63. Over the last five days, the stock has lost -32.08%. Zentalis Pharmaceuticals Inc shares have fallen nearly -46.20% since the year began. Nevertheless, the stocks have fallen -86.06% over the past one year. While a 52-week high of $18.07 was reached on 01/03/25, a 52-week low of $1.62 was recorded on 02/04/25. SMA at 50 days reached $2.8982, while 200 days put it at $5.0578.
Levels Of Support And Resistance For ZNTL Stock
The 24-hour chart illustrates a support level at 1.5900, which if violated will result in even more drops to 1.5500. On the upside, there is a resistance level at 1.6900. A further resistance level may holdings at 1.7500. The Relative Strength Index (RSI) on the 14-day chart is 27.97, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.4531, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.48%. Stochastics %K at 4.13% indicates the stock is a buying.
How much short interest is there in Zentalis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Zentalis Pharmaceuticals Inc stocks on 2025-01-15, dropping by -0.42 million shares to a total of 5.08 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 5.5 million shares. There was a decline of -8.31%, which implies that there is a negative sentiment for the stock.
